晚期非小细胞肺癌患者维持检查点抑制剂治疗的最佳持续时间 - Suppr

Suppr

超能文献

Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC.

作者信息

Shukla Nikhil, Hanna Nasser, Durm Greg

机构信息

Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.

出版信息

JCO Oncol Pract. 2021 Aug;17(8):472-474. doi: 10.1200/OP.21.00059. Epub 2021 May 3.

DOI:10.1200/OP.21.00059

PMID:33939474

Abstract

摘要

相似文献

Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC.晚期非小细胞肺癌患者维持检查点抑制剂治疗的最佳持续时间

JCO Oncol Pract. 2021 Aug;17(8):472-474. doi: 10.1200/OP.21.00059. Epub 2021 May 3.

[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].[PD-1/PD-L1检查点抑制剂治疗非小细胞肺癌的临床研究进展]

Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):440-448. doi: 10.3779/j.issn.1009-3419.2019.07.06.

Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。

Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.

Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.免疫检查点抑制剂作为晚期非小细胞肺癌的一线及挽救治疗

Future Oncol. 2016 Aug;12(15):1805-22. doi: 10.2217/fon-2016-0086. Epub 2016 Jun 8.

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况

BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.

[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or  Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]

Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.

Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗时抗生素的预测影响：抗生素免疫检查点抑制剂在晚期 NSCLC 中的应用。

Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.

[Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers].[IV期非小细胞肺癌。局部晚期非小细胞肺癌的化疗疗程]

Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S72-16S77.

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.携驱动基因突变的肺癌的免疫检查点阻断：择路需明智。

Am Soc Clin Oncol Educ Book. 2020 May;40:372-384. doi: 10.1200/EDBK_280795.

Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.晚期非小细胞肺癌患者中抗 PD-1 和抗 PD-L1 抗体免疫检查点抑制剂再挑战时的给药切换：病例系列和文献复习。

Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.

引用本文的文献

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer.早期和局部晚期非小细胞肺癌管理中微小残留病的全面概述。

NPJ Precis Oncol. 2025 Jun 13;9(1):178. doi: 10.1038/s41698-025-00984-9.

Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study.帕博利珠单抗治疗持续时间对晚期非小细胞肺癌总生存期及预后因素的影响：一项全国性回顾性队列研究

Lancet Reg Health Eur. 2024 Jun 29;43:100970. doi: 10.1016/j.lanepe.2024.100970. eCollection 2024 Aug.

Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group.老年局部晚期头颈部皮肤鳞状细胞癌患者的免疫治疗与低分割放疗：国际老年放疗小组提出的范例

Cancers (Basel). 2023 Oct 13;15(20):4981. doi: 10.3390/cancers15204981.

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.循环肿瘤 DNA 监测在化疗免疫治疗中的应用：用于晚期非小细胞肺癌的风险分层。

Clin Cancer Res. 2023 Nov 14;29(22):4596-4605. doi: 10.1158/1078-0432.CCR-23-1578.

Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer.抗 PD-1 免疫治疗联合剂量调整超分割再放疗治疗局部复发性头颈部肿瘤。

Clin Transl Oncol. 2023 Oct;25(10):3032-3041. doi: 10.1007/s12094-023-03172-y. Epub 2023 Apr 14.

Is anti-PD-1 immunotherapy a means for post-irradiation tumor clearance in head and neck cancer?抗 PD-1 免疫治疗是否是头颈部癌症放疗后肿瘤清除的一种手段？

Med Oncol. 2022 Sep 7;39(12):186. doi: 10.1007/s12032-022-01778-w.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验